Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: Australia, Germany, United Kingdom, United States, France
The Baltics, consisting of Estonia, Latvia, and Lithuania, have seen a steady growth in the Immunosuppressants market in recent years.
Customer preferences: Patients in the Baltics suffering from autoimmune diseases, organ transplants, and other conditions that require immunosuppressants have been increasingly opting for biologic drugs over traditional drugs. Biologics are seen as more effective and have fewer side effects compared to traditional drugs. Patients in the Baltics also prefer to use generic versions of immunosuppressants due to their lower cost.
Trends in the market: The Immunosuppressants market in the Baltics is expected to continue to grow due to the increasing prevalence of autoimmune diseases and organ transplants. The market is also expected to benefit from the increasing use of biologics and generic drugs. The market is expected to see increased competition as more companies enter the market and as more biologics go off-patent.
Local special circumstances: The Baltics have a relatively small population, which limits the size of the Immunosuppressants market. However, the market is expected to benefit from the increasing availability of healthcare services in the region. The region has also seen an increasing number of medical tourists, which has helped to boost the Immunosuppressants market.
Underlying macroeconomic factors: The Immunosuppressants market in the Baltics is influenced by a number of macroeconomic factors. The region has a relatively low GDP per capita, which limits the ability of patients to pay for expensive drugs. However, the region has seen increasing economic growth in recent years, which has helped to boost the Immunosuppressants market. The region also has a well-developed healthcare system, which has helped to support the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)